Circulating Tumor Cell Market Opportunities and Forecast On Top Players
Posted by Rohit Kamble on January 28th, 2020
Circulating Tumor Cell (CTC) Market Share, Growth and Trends Analysis By Application (Research, Drug Development), Technology (CTC Enrichment, CTC Detection), End-User (Hospital & Clinics, Research & Academic Institutes, Diagnostic Centers) - Global Forecast Till 2023
The Circulating Tumor Cell Market report offers insights into the leading market players and presents an assessment of their current market position. Company information with regards to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M&A activities, and the latest R&D initiatives is also available in the report
Major Key Players
To gain a substantially large competitive advantage, these players incorporate strategic initiatives such as mergers & acquisitions, collaboration, expansion, and product launch. Due to the increasing strategic partnerships, the structure of the market is changing rapidly. Besides, the growing competition in the market is encouraging multinational companies to acquire small yet promising companies operating in the developing markets.
Ikonisys Inc., Greiner Bio-One International GmbH, Thermo Fisher Scientific, SRI International, STEMCELL Technologies, Miltenyi Biotec, Menarini Silicon Biosystems, QIAGEN Hannover (QIAGEN), F. Hoffmann-La Roche Ltd, NanoString Technologies, Inc, Fluxion Biosciences, Inc., GE Healthcare, ApoCell, Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation), Epic Lifesciences, Celltraffix Inc and Others.
Market Segment Analysis
In November 2017: Epic Sciences, Inc. announces the release of its breast cancer single-cell profiling panel. This epics breast cancer panel is the most complete breast cancer biomarker panel available for classification of circulating tumour cells (CTCs) within a blood sample. Moreover, multiple biopharma and academic institutes are vigorously utilizing the panel as a clinical research tool to analyse the influence of dozens of novel and standard of care therapies in context to biochemical drivers of disease progression.
Further in November 2017 Clearbridge BioMedics and Leica Biosystems had an partnership to Co-market Automated Solutions for Circulating Tumor Cell (CTC) Analysis. This is precisely for the Clearbridge BioMedics ClearCell FX CTC enrichment system and the Leica Biosystems BOND RX staining platform. This new partnership provides an incorporated and mechanised workflow for circulating tumour cells CTC enrichment and immunostaining, improving on major challenges in circulating tumour cells CTC liquid biopsy testing, such as handling and standardization.
Top of Form
Key Study Highlights:
Geographically, the global Circulating Tumor Cell Market has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
Browse Full Report Page Enabled with complete Table of Content at https://www.marketresearchfuture.com/reports/circulating-tumor-cell-market-1362
Chapter 9. Global Circulating Tumor Cell Market By Region
9.2.1 North America
9.2.2 South America
9.3.1 Western Europe
126.96.36.199 Rest Of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.5 Republic Of Korea
9.4.6 Rest Of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.6 Rest Of The Middle East & Africa
About Market Research Future: MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
+1 646 845 9312 | Email: firstname.lastname@example.org
Like it? Share it!
About the AuthorRohit Kamble
Joined: February 25th, 2019
Articles Posted: 194
More by this author